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Purpose: To evaluate the heritability of choroidal thickness and its relationship to age-related macular
degeneration (AMD).
Design: Cohort study.
Participants: Six hundred eighty-nine individuals from Amish families with early or intermediate AMD.
Methods: Ocular coherence tomography was used to quantify choroidal thickness, and fundus photography
was used to classify eyes into categories using a modiﬁed Clinical Age-Related Maculopathy Staging (CARMS)
system. Repeatability and heritability of choroidal thickness and its phenotypic and genetic correlations with the
AMD phenotype (CARMS category) were estimated using a generalized linear mixed model (GLMM) approach
that accounted for relatedness, repeated measures (left and right eyes), and the effects of age, gender, and
refraction.
Main Outcome Measures: Heritability of choroidal thickness and its phenotypic and genetic correlation with
the AMD phenotype (CARMS category).
Results: Phenotypic correlation between choroidal thickness and CARMS category was moderate (Spear-
man’s rank correlation, rs ¼ 0.24; n ¼ 1313 eyes) and signiﬁcant (GLMM posterior mean, 4.27; 95% credible
interval [CI], 7.88 to 0.79; P ¼ 0.02) after controlling for relatedness, age, gender, and refraction. Eyes with
advanced AMD had thinner choroids than eyes without AMD (posterior mean, 73.8; 95% CI, 94.7 to 54.6;
P < 0.001; n ¼ 1178 eyes). Choroidal thickness was highly repeatable within individuals (repeatability, 0.78; 95%
CI, 0.68 to 0.89) and moderately heritable (heritability, 0.40; 95% CI, 0.14 to 0.51), but did not show signiﬁcant
genetic correlation with CARMS category, although the effect size was moderate (genetic correlation, 0.18; 95%
CI, 0.49 to 0.16). Choroidal thickness also varied with age, gender, and refraction. The CARMS category
showed moderate heritability (heritability, 0.49; 95% CI, 0.26 to 0.72).
Conclusions: We quantify the heritability of choroidal thickness for the ﬁrst time, highlighting a heritable,
quantitative trait that is measurable in all individuals regardless of AMD affection status, and moderately
phenotypically correlated with AMD severity. Choroidal thickness therefore may capture variation not captured by
the CARMS system. However, because the genetic correlation between choroidal thickness and AMD severity
was not signiﬁcant in our data set, genes associated with the 2 traits may not overlap substantially. Future studies
should therefore test for genetic variation associated with choroidal thickness to determine the overlap in genetic
basis with AMD. Ophthalmology 2016;123:2537-2544 ª 2016 by the American Academy of Ophthalmology. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Age-related macular degeneration (AMD) is a major cause
of blindness in older adults.1 Both demographic and
environmental factors, including advanced age, gender,
smoking history, and diet, contribute to the risk of AMD
developing.2e4 Intermediate and advanced AMD are also
heritable (heritability [the proportion of phenotypic variation
that is explained by genetic differences], 0.44e0.715,6), with
several common and rare genetic risk factors.4,7 Although
identiﬁed genetic variants explain a relatively large pro-
portion (40%e60%) of the heritability of advanced disease,
a substantial portion remains unexplained.6,7 Progression of
AMD also is poorly understood and highly variable.8 In
addition to unidentiﬁed rare variants or interaction effects,ª 2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.residual variation in disease risk, heritability, and
progression may be partly a reﬂection of the currently
used classiﬁcation for AMD.
Despite the complexity of the AMD phenotype, eyes
usually are classiﬁed into discrete categories using the Age-
Related Eye Disease Study (AREDS)9,10 or simpliﬁed
Clinical Age-Related Maculopathy Staging (CARMS) clas-
siﬁcation systems,11 which are based largely on the presence
and size of key hallmarks of AMD, such as drusen or retinal
pigmentation. Furthermore, most studies of genetic
association compare individuals with no or few signs of
AMD (controls or CARMS categories 1 and 2) with those
with late-stage disease (CARMS categories 4 and 5),2537http://dx.doi.org/10.1016/j.ophtha.2016.09.001
ISSN 0161-6420/16
Table 1. Modiﬁed Clinical Age-Related Maculopathy Staging
Classiﬁcation System11
Category Description
0 No drusen
1 <20 Hard drusen
2 >20 Hard drusen or some medium drusen
3 >20 Medium drusen or a single large drusen
4 Foveal geographic atrophy
5 Choroidal neovascularization
Ophthalmology Volume 123, Number 12, December 2016whereas only a few studies have considered the genetics of
early or intermediate AMD or speciﬁc AMD subtypes.6,12,13
Such broad-scale classiﬁcation of disease stages may not
adequately represent the biological basis of the disease and
may mask important subphenotypes that are linked more
directly to the underlying disease process. Features found in
AMD cases also may overlap with other retinal diseases that
have a distinct genetic basis, confounding our ability to
predict disease risk. We hypothesized that parsing the com-
plex AMD phenotype into heritable ﬁner-scale retinal traits
that are easily measurable in all individuals and that each
have a relatively simple genetic basis (endophenotypes14)
will increase our understanding of the biological basis of
AMD, enabling better prediction of disease risk and
progression, and aiding the discovery of novel drug
targets.15,16 For example, an endophenotype approach was
used recently to identify ocular traits and genes associated
with glaucoma15,17 and myopia.18
Because of recent technological advances, spectral-
domain (SD) ocular coherence tomography (OCT) now
allows detailed cross-sectional imaging of the retina’s
ultrastructure, offering enhanced detection, measurement,
and analysis of retinal traits beyond those offered by tradi-
tional fundus photography.19 Therefore, SDOCTmay aid the
identiﬁcation of AMD endophenotypes or biomarkers that
can be used to predict risk or progression to advanced
stages.20,21 Traits such as choroidal thickness,22,23 drusen
volume,20 and the presence of reticular pseudodrusen20,24
have been linked previously to AMD disease status and
progression and may deﬁne AMD endophenotypes. For
example, choroidal thickness was found to decrease with
increasing AMD severity (AREDS categories 1e4).23
However, most studies have measured only the overall
phenotypic correlation between retinal traits and AMD, but
phenotypic correlation may result from genetic correction
(overlapping genes), environmental correlation, or both. If
environmental factors drive the correlation between retinal
traits and AMD, rather than the same genes, then
performing genetic association analyses on these ﬁne-scale
retinal traits may not be informative for AMD. Therefore,
the relationship between retinal features, AMD risk and
progression, and genetics is unclear and requires further
investigation. Speciﬁcally, for a trait to be useful as an AMD
endophenotype requires that the trait is shown to be heritable
and genetically correlated, to some extent, with the AMD
phenotype, that is, that there is some shared genetic basis
between the quantitative trait and the disease.14,15,25 Such
analyses can be performed by measuring the phenotypic
similarity and relatedness between family members in a
pedigree or twin study because this allows phenotypic vari-
ation to be separated into genetic variation, environmental
variation, and individual-level variation (repeatability).
To assess the use of choroidal thickness as an AMD
endophenotype for future genetic studies, we examined
whether the trait is heritable (i.e., whether a signiﬁcant pro-
portion of the phenotypic variation is explained by genetic
variation) and phenotypically and genetically correlated with
the AMD phenotype (CARMS category) using families from
the Amish Eye Study. The Amish are genetically and
culturally isolated, and experience a relatively uniform2538environment, reducing genetic diversity and variance in dis-
ease risk. Additionally, their large extended families provide a
powerful tool for heritability analyses. The frequency of
smoking (a key environmental risk factor for AMD2) also is
low. The Amish therefore provide an excellent opportunity
to examine the genetic architecture of complex disease.
Methods
Study Population and Data Collection
Participants were recruited from Amish populations in Lancaster
County, Pennsylvania; Holmes County, Ohio; and Elkhart and
LaGrange Counties, Indiana. Informed consent was obtained from
all individuals. Institutional review board approval was obtained,
and research complied with the Health Insurance Portability and
Accountability Act and adhered to the tenets of the Declaration of
Helsinki. Individuals and their siblings were recruited from fam-
ilies with at least 2 affected individuals with early or intermediate
AMD. Recruited families varied in size from nuclear families of up
to 13 siblings to extended families of up to 30 individuals.
At each clinical center (Indiana, Ohio, Pennsylvania) participants
underwent a health history and ophthalmologic examination that
included color fundus photography and SD OCT volume scans for
both eyes where possible. For choroidal thickness assessments, SD
OCT imaging was performed with the Spectralis OCT device (Hei-
delberg Engineering, Inc., Heidelberg, Germany) using a 2020
ﬁeld of view centered on the fovea with 97 B-scans each comprising
512 A-scans. Images were exported to the Doheny Image Reading
Center and the choroidal thicknesswasmeasured at the foveal center,
from the lower border of the retinal pigment epitheliumeBruch’s
membrane band to the choroidalescleral junction, using the caliper
tool in the HEYEX (Heidelberg, Germany) software, in accordance
with previous reports from the reading center.26 Eyes were classiﬁed
by amodiﬁed CARMS classiﬁcation (categories 0e5) at the Doheny
Center from color fundus photographs (Table 1). The CARMS
system grades eyes from 1 to 511 and considers eyes with no
drusen and few small drusen as category 1. To achieve a more
granular phenotype, for this analysis, eyes with no drusen were
assigned to a new category of 0, whereas only those with a few
small drusen were included in category 1. Category 2 included
eyes with many small drusen or a few medium drusen, and thus
included eyes both without AMD and with early AMD (using the
convention that medium drusen constitute the minimum criteria for
AMD27). Category 3 included eyes with intermediate AMD, and
categories 4 and 5 included eyes with advanced AMD, as in the
CARMS system11 (Table 1).
Statistical Analysis
To assess the use of choroidal thickness as an AMD endopheno-
type we quantiﬁed (1) its overall phenotypic correlation with the
Table 2. Demographic Parameters for 689 Participants
Parameter Pennsylvania Indiana Ohio All
Gender 193 women, 122 men 142 women, 106 men 82 women, 44 men 417 women, 272 men
Age, yrs (mean  SD) 65.610.5 65.511.4 70.19.9 66.410.9
SD ¼ standard deviation.
Sardell et al  Heritability of Choroidal ThicknessAMD phenotype, (2) its heritability, and (3) its genetic correlation
with the AMD phenotype to assess the extent to which genetic
variation underlying the 2 traits overlapped. Our primary analyses
treated the AMD phenotype as an ordinal trait, CARMS category
(0e5), because this approach was more powerful than dichoto-
mizing the phenotype as a binary trait (presence or absence of
AMD). However, in a secondary analysis we reanalyzed data
treating the AMD phenotype as a binary trait where possible.
Broad-sense heritability (the proportion of phenotypic variance
that is explained by genetic variance) of both choroidal thickness
and CARMS category and their correlation were quantiﬁed in a
generalized linear mixed model (GLMM) framework. A GLMM
approach enabled the use of repeated measures (both left and right
eyes per subject) and hence an estimate of the proportion of
phenotypic variance in each trait that was explained by individual
identity (repeatability), the inclusion of covariates such as age, and
it maximized the use of relatedness information from a pedigree.28
Analyses were run using the R-package MCMCglmm (available
at https://cran.r-project.org/web/packages/MCMCglmm/index.html)
that ﬁts models in a Bayesian framework using Markov chain Monte
Carlomethods.29First, a univariateGLMMof choroidal thicknesswas
used to test whether choroidal thickness varied with AMD severity
(CARMS category) while controlling for age, gender, spherical
equivalent refraction (sphere plus half the cylinder), relatedness, and
repeated measures (left and right eyes). A bivariate GLMM with a
2-trait response variable then was ﬁt with CARMS category (0e5)
speciﬁed as an ordinal (threshold) trait with probit link and
choroidal thickness speciﬁed as a Gaussian trait to quantify the
heritability of each trait and their genetic correlation while
controlling for age, gender, and spherical equivalent refraction (as a
covariate for choroidal thickness only). A pedigree (participant,
mother, father) was used to estimate a genetic varianceecovariance
matrix, and a random effect of individual identiﬁcation was ﬁt to
account for repeated measures per person (left and right eyes),
allowing phenotypic variance to be partitioned into genetic,
individual-level, and residual variance. Shared environmental effects
between familymemberswere not accounted for andmay conﬂate our
estimate of genetic variance, but because AMD is a late-onset disease,
it was unclear whether accounting for a shared sibship environment
was relevant.5 Eyes that were missing 1 of the 2 traits (CARMS
category or choroidal thickness; n ¼ 61) were included in analyses
because bivariate GLMMs can handle missing data in the response
variable. In the bivariate model, random effect and residualTable 3. Number of Participants by Modiﬁed Clinical Age-Related Ma
Eyes)
Population
Clinical Age-Related Maculopathy Staging C
0 1 2
Pennsylvania 131 82 43
Indiana 114 75 25
Ohio 45 30 12
Total 290 187 80variances were speciﬁed using the us(trait) structure, thereby
allowing the variance and covariance to vary between the 2 traits.
Default priors were used for ﬁxed effects. Priors on variance
components for residual terms were inverse Wishart distributed with
variance of 1 and a low degree of belief (nu ¼ 0.002), with variance
ﬁxed at 1 for the ordinal trait.29 For random effects, we used
parameter-expanded priors to facilitate mixing with a mean (mu) of
0 and variance (V) of 1000 for choroidal thickness and 100 for
CARMS category.29 Variance estimates were similar when models
were run with alternative priors. Models were run for 10 500 000
iterations with a burn-in interval of 500 000 and thin of 2000 to give
an effective sample size of approximately 5000 and autocorrelation
less than 0.1 between consecutive samples. Model convergence and
mixing were assessed by visual inspection of plots and by using the
heidel.diag function in the Coda package.30 All analyses were
conducted in R version 3.0.1 (available at: http://www.cran.r-
project.org). The heritability of choroidal thickness was
quantitatively similar when run in a (restricted) maximum likelihood
framework using the R package pedigreemm.Results
A total of 689 participants (417 women and 272 men) from Indiana
(n ¼ 248), Pennsylvania (n ¼ 315), and Ohio (n ¼ 126) were
recruited and examined between August 2013 and November 2015
(n ¼ 1378 eyes; Table 2). Mean baseline age of participants was
66.410.9 years (range, 33e99 years). Considering the most
severely affected eye per individual, approximately 42.1% of
participants were CARMS category 0, 27.1% were CARMS
category 1, 11.6% were CARMS category 2, 11.5% were
CARMS category 3, 5.4% had advanced AMD (CARMS
categories 4 or 5), and 2.3% were not graded because of a
fundus camera malfunction at 1 site (Table 3). Mean spherical
equivalent refraction was 0.551.62 diopters for right eyes
and 0.561.65 diopters for left eyes.
Mean choroidal thickness of 679 right eyes was 253.970.6
mm and that of 670 left eyes was 253.569.4 mm (Fig 1).
Choroidal thickness was strongly correlated between left and
right eyes (Pearson’s correlation coefﬁcient, r ¼ 0.82; n ¼
660; Fig 2). As expected, CARMS category also was strongly
correlated between eyes (Spearman’s correlation coefﬁcient,
rs ¼ 0.84; n ¼ 665; Fig 2); therefore, eyes tended to be at theculopathy Staging Classiﬁcation System Category (Most Advanced
lassiﬁcation System Category
Not Graded All3 4 5
36 7 1 15 315
21 8 4 1 248
22 17 0 0 126
79 32 5 16 689
2539
Figure 1. Bar graphs showing the distribution of subfoveal choroidal thickness (in micrometers) for (A) right eyes and (B) left eyes.
Figure 2. Scatterplots showing the phenotypic correlation of (A) Clinical Age-Related Maculopathy Staging (CARMS) category and (B) subfoveal
choroidal thickness between left and right eyes and the correlation between subfoveal choroidal thickness and CARMS category for (C) right eyes and
(D) left eyes. Points have been jittered for visualization.
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Sardell et al  Heritability of Choroidal Thicknesssame disease stage. However, correlation coefﬁcients suggested
that there was sufﬁcient variation to justify the inclusion of
both eyes in future analyses. Choroidal thickness showed
moderate negative phenotypic correlation with CARMS
category (rs ¼ 0.24; n ¼ 1313 eyes; Fig 2); eyes more
severely affected with AMD had thinner choroids. This
correlation was signiﬁcant in a univariate GLMM of choroidal
thickness controlling for relatedness, repeated measures (left
and right eyes), age, gender, and refraction (posterior
mean, 4.27; 95% credible interval [CI], 7.88 to 0.79;
MCMC P value ¼ 0.02). Secondary analyses deﬁning AMD
severity as a binary trait showed that choroidal thickness was
marginally thinner in eyes with AMD (categories 3, 4, and 5;
n ¼ 190 eyes; posterior mean, 10.7; 95% CI, 20.87 to
0.15; MCMC P value ¼ 0.05) compared with eyes with no
AMD (CARMS categories 0, 1, and 2; n ¼ 1123 eyes).
Interestingly, this difference in choroidal thickness between
affected and unaffected individuals was substantially stronger
and signiﬁcant if category 3 (intermediate AMD) eyes were
excluded (posterior mean, 73.8; 95% CI, 94.7 to 54.6;
MCMC P value < 0.001; n ¼ 1178 eyes); therefore, eyes with
advanced AMD had signiﬁcantly thinner choroids than those
without AMD. However, note that the sample size for this
secondary analysis was small (n ¼ 37 individuals with at least
1 advanced AMD eye).
A bivariate GLMM estimated that the repeatability (proportion
of phenotypic variation that was explained by an individual’s
identity) of choroidal thickness was high (0.78; 95% CI, 0.75 to
0.81; n ¼ 1378 eyes) and that the heritability of choroidal thickness
was moderate (0.40; 95% CI, 0.24 to 0.56; Table 4). The CARMS
category also was highly repeatable (0.93; 95% CI, 0.91 to 0.94;
Table 4) and moderately heritable (heritability, 0.49 on the
liability scale; 95% CI, 0.26 to 0.72), similar to that estimated by
a twin study (heritability, 0.465). Choroidal thickness (r ¼ 0.46;
Markov chain Monte Carlo [MCMC] P value < 0.001; Fig 3)
and CARMS category (r ¼ 0.38; MCMC P value < 0.001;
Fig 3) were signiﬁcantly negatively correlated with age, but only
choroidal thickness varied with gender; men had slightly thinner
choroidal thickness (MCMC P value ¼ 0.04; Table 5). Choroidal
thickness also was correlated positively with refraction (Table 5).
Genetic correlation between choroidal thickness and CARMS
category was 0.18, but 95% CIs overlapped 0 (0.49 to 0.16);
therefore, the correlation was not statistically signiﬁcant
(Table 4). The bivariate model also estimated that the overall
phenotypic correlation between choroidal thickness and CARMS
category was moderate, negative, and signiﬁcant (0.14; 95%
CI, 0.22 to 0.06). We did not test for the genetic correlation
between choroidal thickness and the AMD phenotype as a binary
trait because the complexity of a bivariate model and the
relatively small number of advanced AMD cases (62 vs. 1137
eyes with no AMD) prevented model convergence despite long
run time.
Discussion
Decomposing disease phenotypes into heritable sub-
components may be especially useful for unravelling the
complex genetic basis of multifactorial diseases such as
AMD. Endophenotypes also may be useful as biomarkers
of disease risk or progression, thereby inﬂuencing clinical
decision making and allowing for intervention to alter
disease progression.16 Genetic studies of heritable, novel
AMD phenotypes also may provide additional biological
pathways and therapeutic targets for early or intermediate2541
Figure 3. Scatterplots showing the correlation between (A) Clinical Age-Related Maculopathy Staging (CARMS) category and age and (B) subfoveal
choroidal thickness and age. Points are jittered for visualization.
Ophthalmology Volume 123, Number 12, December 2016AMD. One retinal trait that is quantiﬁable in all individuals
using OCT imaging, regardless of AMD disease status, is
choroidal thickness. The choroid performs many of the
retina’s essential metabolic functions, and thinning of the
choroid previously was associated with age and AMD;
older individuals31e33 and those with AMD22,34e39 had
thinner choroids, although some studies did not ﬁnd a
difference with AMD status.33,40e42
Here we show that, after controlling for age, gender, and
refraction, choroidal thickness is phenotypically negatively
correlated with CARMS category and hence the severity of
AMD. Eyes with AMD also had marginally thinner choroids
than those without AMD. Phenotypic but not genetic cor-
relation between choroidal thickness and AMD has been
tested previously. Several studies found that advanced AMD
cases had thinner choroids than controls.34,38,39 Some
studies also found a difference in choroidal thicknessTable 5. Main Effect Parameters (Posterior Mean, 95% Credible
Interval, and MCMC P Values) from a Bivariate Generalized
Linear Mixed Model Investigating Variation in Choroidal
Thickness and Modiﬁed Clinical Age-Related Maculopathy
Staging Category with Respect to Age, Gender, and Refraction
Trait
Posterior
Mean
95% Credible
Interval
MCMC
P Value
Choroidal thickness
intercept (women)
476.1 446.2 to 504.4 <0.001
CARMS category
intercept (women)
11.3 13.6 to 9.1 <0.001
Choroidal thickness: age 3.4 3.8 to 3.0 <0.001
CARMS category: age 0.17 0.1 to 0.2 <0.001
Choroidal thickness: men 8.6 17.1 to 0.5 0.04
CARMS category: men 0 0.6 to 0.6 0.91
Choroidal thickness:
refraction
6.0 3.5 to 8.3 <0.001
CARMS ¼ Clinical Age-Related Maculopathy Staging.
2542between early AMD cases and controls,35e37 whereas others
did not,22,23,41 and some found that the strength of the
correlation depends on the AMD subtype.39,43 We found a
stronger difference between AMD cases and controls when
eyes with intermediate AMD were excluded, albeit with a
small sample of advanced cases, which suggested that the
correlation between choroidal thickness and AMD severity
is driven primarily by the considerable decrease in choroidal
thickness in advanced AMD cases (Fig 2).
Moreover, we showed for the ﬁrst time that choroidal
thickness is signiﬁcantly heritable and therefore has a
substantial genetic component. Choroidal thickness there-
fore may deﬁne an AMD endophenotype useful for genetic
studies. However, for a trait to deﬁne an endophenotype, it
also should show some (but not perfect) genetic correlation
with the disease phenotype. Although the effect size of the
genetic correlation between choroidal thickness and
CARMS category was moderate (0.18), suggesting that
the phenotypic correlation observed between the 2 traits
may reﬂect some overlap in genetic basis, the genetic
correlation was not signiﬁcantly different from 0. Genetic
correlation is the extent to which 2 traits share the same
genes, whereas phenotypic correlation also encompasses
environmental correlation. It is likely that the absence of
signiﬁcant genetic correlation results from relatively low
power to detect correlation with the ordinal trait, CARMS
category, because our study was focused primarily on
families whose members demonstrated early or interme-
diate AMD, and therefore our sample consisted of many
controls (approximately 70% of individuals were cate-
gories 0 or 1) and relatively few individuals with advanced
AMD (5%). Any genetic correlation between choroidal
thickness and AMD may be more likely to be detected
across a sample with a larger proportion of advanced AMD
cases or a more variable sample of unrelated individuals
using genome-wide trait analysis. Finally, CARMS cate-
gory is only 1 measure of AMD severity or presence.
Indeed, many studies dichotomize AMD scales into
Sardell et al  Heritability of Choroidal Thicknesscase-control status to study the genetics of advanced AMD
risk. Our preliminary analyses of this relatively small
sample size suggested that the genetic correlation between
these 2 traits was stronger than that for CARMS category.
Therefore, the absence of a signiﬁcant genetic correlation
in this data set of patients with early or intermediate dis-
ease and their unaffected relatives does not preclude the
use of choroidal thickness as an AMD endophenotype.
Because the correlation between choroidal thickness and
AMD severity was, at most, moderate, choroidal thickness
may capture novel genetic and phenotypic variation and
therefore may be especially informative for future studies of
AMD. Numerous common and rare variants are associated
with advanced AMD,7 although cumulatively they explain
no more than 60% of the heritability of advanced disease,
and less for early or intermediate AMD.6,12 Age-related
macular degeneration endophenotypes may be associated
with a subset of these known AMD variants, with novel
variants, or with both. Cohort studies focusing on families
are especially useful for detecting genetic causes of disease,
and the Amish Eye Study is such a resource. Finding the
genetic causes for choroidal thickness has the potential to
uncover novel biology for the progression of early to late
AMD and ultimately may lead to better prognostic in-
dicators and treatments to prevent AMD.
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